Almac Collect Top Recognition for New Ovarian Cancer Research Product

March 10, 2009

Almac Diagnostic Services has received a top recognition from the Cambridge Healthtech Institute for a pioneering product specifically designed to aid ovarian cancer research.  The company collected a ‘Best New Product’ award at the Institute’s Third Annual Awards held in San Francisco in February.

The award was presented for work on their Ovarian Cancer DSA™ research tool. The product is the first high-density disease focused transcriptome based microarray for the study of ovarian cancer. With over 100,000 transcripts derived from ovarian tissue, the Ovarian Cancer DSA™ research tool represents the most complete platform available for the study of ovarian cancer.

Managing Director of Almac Diagnostic Services and Professor of Molecular Oncology within the Cancer Research Center at Queen’s University Belfast, Professor Paul Harkin said; “I am delighted with this recognition by the Cambridge Healthtech Institute. The Ovarian Cancer DSATM adds to our Cancer DSATM range of microarray based research tools, enabling further discovery in cancer research.

“Our Ovarian Cancer DSA™ has the potential to lead to the development of targeted therapies to tackle ovarian cancer,” he added.

Almac have also developed DSA™ research tools for colorectal, lung, breast and prostate cancer.

The news comes one week after Almac won the Invest Northern Ireland ‘Exporter of the Year’ award for outstanding export achievement and growth. The award follows a successful 2008 for the organization which generates over 70% of its sales from export.

ENDS

Notes to the Editor:

About Almac Diagnostic Services:

Almac Diagnostic Services provides translational genomic based solutions for pharma, biotech and academia. Almac specializes in working with fresh and FFPE tissue for generation of predictive and prognostic tests, drug development, target identification and companion diagnostics.

About Almac Group:

The Almac Group comprises five closely integrated divisions offering a broad range of services from R&D, translational genomic services, API manufacture, formulation development, clinical trial supply and technology (IVRS/Web/EDC), to commercial-scale manufacture. Almac provides services to more than 600 companies, including all the world leaders in the pharmaceutical and biotech sectors.

The company employs over 2,400 individuals and is headquartered in Craigavon, Northern Ireland. US operations are based in Pennsylvania, North Carolina and California. Construction of the company’s new $100m North American Headquarters started in July 08 and is expected to be completed 2010. For more information about the Almac Group, please visit www.almacgroup.com.

About Cambridge Healthtech Institute (CHI)

Founded in 1992, Cambridge Healthtech Institute (www.chicorporate.com) is the pre-eminent life science network for leading researchers and business experts from top pharmaceutical, biotech, academic, and niche service provider organizations. CHI’s integrated life science portfolio of products and services includes Cambridge Healthtech Institute Conferences, Pharmaceutical Strategy Series, Barnett International, Insight Pharma Reports, Marketing Services, Meeting Planners, and Cambridge Healthtech Media Group, which includes numerous eNewsletters, Bio-IT World magazine, as well as Lead Generation Programs.

Contact

Carl Whyte

Stakeholder Communications

02890 339949

Joseph Cushley

Almac Diagnostic Services

028 3839 7575

diagnostics@almacgroup.com

< Back to News Page

Share

Back to news